MyMedR

Displaying all 4 publications

Abstract:

Sort:

Combination of transcranial direct current stimulation and methylphenidate in subacute stroke

Wang QM, Cui H, Han SJ, Black-Schaffer R, Volz MS, Lee YT, et al.

Neurosci Lett, 2014 May 21;569:6-11.
PMID: 24631567 DOI: 10.1016/j.neulet.2014.03.011

Noninvasive transcranial direct current stimulation (tDCS) and methylphenidate (MP) are associated with motor recovery after stroke. Based on the potentially complementary mechanisms of these interventions, we examined whether there is an interactive effect between MP and tDCS. In this preliminary study, we randomized subacute stroke subjects to receive tDCS alone, MP alone or combination of tDCS and MP. A blinded rater measured safety, hand function, and cortical excitability before and after treatment. None of the treatments caused any major or severe adverse effects or induced significant differences in cortical excitability. Analysis of variance of gain score, as measured by Purdue pegboard test, showed a significant between-group difference (F(2,6)=12.167, p=0.008). Post hoc analysis showed that the combination treatment effected greater Purdue pegboard gain scores than tDCS alone (p=0.017) or MP alone (p=0.01). Our preliminary data with nine subjects shows an interesting dissociation between motor function improvement and lack of motor corticospinal plasticity changes as indexed by transcranial magnetic stimulation in subacute stroke subjects.

Matched MeSH terms: Central Nervous System Stimulants/therapeutic use*
Autism and trichotillomania in an adolescent boy

Masiran R

BMJ Case Rep, 2018 Sep 05;2018.
PMID: 30185454 DOI: 10.1136/bcr-2018-226270

An adolescent with autism spectrum disorder and improperly treated attention deficit hyperactivity disorder presented with recurrent hair pulling. Treatment with selective serotonin reuptake inhibitor and stimulant improved these conditions.

Matched MeSH terms: Central Nervous System Stimulants/therapeutic use*
The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review

Andrew BN, Guan NC, Jaafar NRN

Curr Drug Targets, 2018;19(8):877-887.
PMID: 28322161 DOI: 10.2174/1389450118666170317162603

BACKGROUND: One of the goals of cancer treatment is symptoms management especially at the end stage. The common symptoms in cancer include pain, fatigue, depression and cognitive dysfunction. The available treatment options for symptom management are limited. Methylphenidate, a psychostimulant, may be of benefit for these patients. In this report, we review the use of methylphenidate for symptoms control in cancer patients.
METHOD: Electronic literature search on PubMed was conducted using the following keywords: methylphenidate, cancer, carcinoma, oncology, oncological and tumour. We identified forty two relevant studies and publications on the use of methylphenidate in cancer patients to be included in this review.
RESULTS: Methylphenidate was found to have some evidence in reducing opioid-induced sedation, improving cognitive symptoms and reduction of fatigue in cancer patients. Nevertheless, the results were inconsistent due to variations in the study populations, study design and outcome measures, among others. There was minimal evidence on its use in treating depression. Otherwise, methylphenidate was generally well-tolerated by patients.
CONCLUSION: This review potentially supports the use of methylphenidate for opioid-induced sedation, cognitive decline and fatigue in cancer patients. Further placebo-controlled trials would help in strengthening the evidence for this treatment.

Matched MeSH terms: Central Nervous System Stimulants/therapeutic use*
Case Series

Vetrayan J, Othman S, Victor Paulraj SJ

J Atten Disord, 2017 01;21(2):168-179.
PMID: 23529885 DOI: 10.1177/1087054713479665

OBJECTIVE: To assess the effectiveness and feasibility of behavioral sleep intervention for medicated children with ADHD.
METHOD: Six medicated children (five boys, one girl; aged 6-12 years) with ADHD participated in a 4-week sleep intervention program. The main behavioral strategies used were Faded Bedtime With Response Cost (FBRC) and positive reinforcement. Within a case-series design, objective measure (Sleep Disturbance Scale for Children [SDSC]) and subjective measure (sleep diaries) were used to record changes in children's sleep.
RESULTS: For all six children, significant decrease was found in the severity of children's sleep problems (based on SDSC data). Bedtime resistance and mean sleep onset latency were reduced following the 4-week intervention program according to sleep diaries data. Gains were generally maintained at the follow-up. Parents perceived the intervention as being helpful.
CONCLUSION: Based on the initial data, this intervention shows promise as an effective and feasible treatment.

Matched MeSH terms: Central Nervous System Stimulants/therapeutic use